New drug delivery technology for “Cystic Fibrosis” (Ivacaftor)

  • Published on
    23-Jan-2018

  • View
    10

  • Download
    0

Transcript

New drug delivery technology for Cystic FibrosisContentsDrug delivery systemCystic fibrosisIvacaftorTraditional dosage form of IVACAFTORProposed dosage formAdvantages of the proposed dosage formSide-effect reduction of proposed dosage formConclusionDrug delivery system Refers to the technology which is utilized to present the drug to the desired body site for drug release & absorption.Cystic fibrosis A progressive & genetic disease that causes persistent lung infections and limits the ability to breathe over time. It may also affects the pancreas, liver, kidneys, and intestine.Drugs used to treat cystic fibrosisIvacaftor Formula : C24H28N2O3 Molecular Weight : 392.490 g/mol Generic name : Ivacaftor. Brand name : Kalydeco. Drug approved : Jan 31,2012. Cystic fibrosis usage approved : May 17,2017.Traditional dosage form of IVACAFTOR TabletFilm-coatedOral Granules.Proposed dosage formBuccal Tablet. A topical route of administration by which drugs are applied in the cheek at canine fossa through the diffusion of oral mucosa which enters directly into the bloodstream.Advantages of the proposed dosage form1. Better Bio-availability : Traditional dosage forms of Ivacaftor has 99% protein binding. So bio-availability is almost lowest.2. Rapid onset of action : Tmax is around 3-5 hours. So it takes more time to show its therapeutic effect.3. Avoid first-pass metabolism : By liver due to direct entry into the bloodstream.Side-effect reduction of proposed dosage form1. Soar throat : Pain or irritation of the throat caused by inflammation & trauma. (Local)2. Sneezing : Uncontrollable expulsion of air through the nose & mouth. (Local)3. Runny nose : Production of extra mucus by the nose.(Local)Side-effect reduction of traditional dosage form4. Nasal congestion : Blockage of the nasal passages usually due to inflamed blood vessels. (Local)5. Loss of appetite.Conclusion Ivacaftor was sold for $339M in USA during the year of 2014 for other indications. As its usage for cystic fibrosis is approved by US-FDA recently, it has huge opportunity to do well in this disease condition too. Also if we can successfully formulate the buccal form of Ivacaftor, then it will boost the usages & sales of Ivacaftor further more. References 1. https://en.wikipedia.org/wiki/Cystic_fibrosis 2. https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/ 3. http://www.deltagene.eu/cftr 4. https://en.wikipedia.org/wiki/Ivacaftor 5. https://en.wikipedia.org/wiki/First_pass_effect 6. https://www.drugs.com/kalydeco.html 7. https://www.drugs.com/sfx/kalydeco-side-effects.html 8. https://www.drugs.com/dosage/kalydeco.html

Recommended

View more >